PMID- 31560661
OWN - NLM
STAT- MEDLINE
DCOM- 20191112
LR  - 20211204
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 292-293
DP  - 2019 Jul-Aug
TI  - [ASSOCIATION OF FIBROBLAST GROWTH FACTOR 23 WITH MARKERS OF INFLAMMATION AND 
      FIBROSIS IN DIABETIC NEPHROPATHY].
PG  - 44-49
AB  - The aim of the present study was to establish the disorders of mineral metabolism 
      and production of monocyte chemoattractant protein type 1 (MCP-1) and plasminogen 
      activator inhibitor type 1 (PAI-1) in patients with diabetic nephropathy (DN) at 
      different stages of the disease. We examined 78 patients with DN aged from 57 to 
      76 years. Fibroblast growth factor 23 (FGF23), MCP-1 and PAI-1 levels in blood 
      serum were determined by ELISA. The levels of calcium and phosphorus in the serum 
      were established by biochemical method. Our results showed the progressive 
      elevation of FGF-23 level in serum depending on the stage of the DN (p <0.05). 
      High levels of FGF23 were determined already in the early stages of nephropathy. 
      FGF23 levels in DN patients twice exceeded control group level. The highest FGF23 
      concentrations were detected in the late stages of the disease. Hyperphosphatemia 
      was found in the late stages of the DN when compared with controls and early 
      preclinical stages. We found a significant increase of MCP-1 and PAI-1 levels in 
      patients with DN. These changes may be involved in inflammatory and fibrotic 
      processes in the kidneys. FGF23 elevation in the peripheral blood of DN patients 
      was associated with an increase of inflammatory and fibrosis mediators MCP-1 and 
      PAI-1. We conclude that FGF23 increase may be considered as an important risk 
      factor of DN progression.
FAU - Topchii, I
AU  - Topchii I
AD  - L.T. Mala National Institute of Therapy of the National Academy of Medical 
      Science of Ukraine, State Institution, Department of Prevention and Treatment of 
      Kidney Diseases at Comorbid Conditions.
FAU - Semenovykh, P
AU  - Semenovykh P
AD  - L.T. Mala National Institute of Therapy of the National Academy of Medical 
      Science of Ukraine, State Institution, Department of Prevention and Treatment of 
      Kidney Diseases at Comorbid Conditions.
FAU - Galchiskaya, V
AU  - Galchiskaya V
AD  - L.T. Mala National Institute of Therapy of the National Academy of Medical 
      Science of Ukraine, State Institution, Department of Prevention and Treatment of 
      Kidney Diseases at Comorbid Conditions.
FAU - Yakymenko, Yu
AU  - Yakymenko Y
AD  - L.T. Mala National Institute of Therapy of the National Academy of Medical 
      Science of Ukraine, State Institution, Department of Prevention and Treatment of 
      Kidney Diseases at Comorbid Conditions.
FAU - Shcherban, T
AU  - Shcherban T
AD  - L.T. Mala National Institute of Therapy of the National Academy of Medical 
      Science of Ukraine, State Institution, Department of Prevention and Treatment of 
      Kidney Diseases at Comorbid Conditions.
LA  - rus
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (FGF23 protein, human)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 7Q7P4S7RRE (Fibroblast Growth Factor-23)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Diabetic Nephropathies/blood/*diagnosis
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibroblast Growth Factor-23
MH  - Fibroblast Growth Factors/*blood
MH  - Fibrosis
MH  - Humans
MH  - Hyperphosphatemia/blood
MH  - Inflammation/blood
MH  - Middle Aged
MH  - Plasminogen Activator Inhibitor 1/*blood
EDAT- 2019/09/29 06:00
MHDA- 2019/11/13 06:00
CRDT- 2019/09/28 06:00
PHST- 2019/09/28 06:00 [entrez]
PHST- 2019/09/29 06:00 [pubmed]
PHST- 2019/11/13 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2019 Jul-Aug;(292-293):44-49.